HEALTHCARE, A FLAGSHIP OF FRENCH INDUSTRY
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
1
BUSINESS FRANCE FRENCH HEALTHCARE 2019
HEALTHCARE,
A FLAGSHIP
OF FRENCH INDUSTRYCONTENTS
3
BUSINESS FRANCE FRENCH HEALTHCARE 2019
_1_ _2_
French healthcare France, an attractive country
industries focused FRANCE IS AN OPEN COUNTRY
on innovation 22
RENOWNED MEDICAL EXCELLENCE
FRENCH HEALTHTECHS RAISE FUNDS
8
25
GLOBALLY ACCLAIMED RESEARCH CENTERS
FRANCE STANDS OUT IN INTERNATIONAL RANKINGS
9 FOR THE QUALITY OF ITS RESEARCH AND ITS INNOVATION
CAPACITY
SUBSTANTIAL R&D INVESTMENTS 25
11
THEY CHOSE FRANCE
26
A COUNTRY WHERE IT’S GOOD TO INNOVATE
13
_3_
A MARKET AT THE HEART OF EUROPE
16 Expertise going global
FRENCH EXPORTS OF
EARLY ACCESS TO INNOVATIONS
MEDICINAL PRODUCTS
17
32
FRANCE, A HEALTHTECH COUNTRY AT THE FRENCH EXPORTS OF
FOREFRONT OF INNOVATION MEDICAL DEVICES
20 34
REGIONAL BREAKDOWN
OF FRENCH EXPORTS
35
25
BUSINESS FRANCE FRENCH HEALTHCARE 2019
KEY FIGURES
13 NOBEL
prizes
in medicine
FRANCE IS MEDICINAL
Healthcare, a flagship
THE SECOND PRODUCTS of French industry
LARGEST Healthcare has always been a central industrial activity in the French
MARKET economy. Today, there are more than 3,000 healthcare businesses in
France, generating revenues of nearly €90 billion.1
IN EUROPE Within these healthcare industries, the 247 pharmaceutical businesses
hold a prominent role, being responsible for €54 billion in revenues and
for medicinal employing nearly 100,000 people.2 This industry is very internationally
products and focused, achieving half of its revenues through exports.
medical devices • 240 businesses France is the fifth large producer of medicinal products in the European
Union.3 Furthermore, France has the second largest number of healthcare
at manufacturer • Revenues: €54 biotechnology businesses (720), of which the great majority are SMEs
and startups.4
prices billion, including 50%
The medical devices sector has more than 1,300 businesses (of which
through exports nearly 900 are innovative SMEs in MedTech and diagnostics),5 of which
• 99,000 employed 92% are micro-enterprises and SMEs. These businesses generate revenues
of nearly €30 billion and employ nearly 85,000 people. The number of
*Source: LEEM businesses has grown very strongly in recent years, from 1,080 in 2011 to
more than 1,340 businesses in 2017.6
France is the fifth largest market in world and the second largest in Europe
for both medicinal products for human use and medical devices.7
INNOVATIVE SMES
*Source: LEEM, MedTech Europe • 720 health and
biotechnologies SME
businesses
• 886 MedTech and
MEDICAL DEVICES diagnostic SME
businesses
• 1,343 businesses
• Revenues: €28 billion,
including €8 billion
through exports
• 85,000 employed Strategic Council of Healthcare Industries (CSIS)1 - Trade Organization of Medical Devices Businesses (LEEM)2 - European Federation of Pharmaceutical
Industries and Associations (EFPIA)3 - France Biotech4 - Businesses with less than 250 employees, whose R&D spending amounts to at least 15% of their total
*Source: SNITEM *Source: France Biotech expenses5 - National Association of the Medical Technologies Industry (SNITEM)6 - Trade Organization of Medical Devices Businesses (LEEM), MedTech Europe7
47
BUSINESS FRANCE FRENCH HEALTHCARE 2019
_1_
RENOWNED MEDICAL EXCELLENCE
8
FRENCH HEALTHCARE GLOBALLY ACCLAIMED RESEARCH CENTERS
INDUSTRIES FOCUSED
9
SUBSTANTIAL R&D INVESTMENTS
ON INNOVATION 11
A COUNTRY WHERE IT’S GOOD TO INNOVATE
13
A MARKET AT THE HEART OF EUROPE
16
EARLY ACCESS TO INNOVATION
17
FRANCE, A HEALTH TECH COUNTRY AT THE
FOREFRONT OF INNOVATION
18
69
BUSINESS FRANCE FRENCH HEALTHCARE 2019
GLOBALLY ACCLAIMED Sanofi, a French
RESEARCH CENTERS
innovation champion
FRENCH HEALTHCARE French research organizations are among the best
in the world. R&D spending
INDUSTRIES FOCUSED
1st business in France
France and the United States are the only two
6th pharmaceutical business
countries to have organizations in Scimago’s top
in the world
15 healthcare research institutes. For France, the
ON INNOVATION
French National Institute for Health and Medical 19th business in the world
Research (Institut national de la santé et de la For the number of patents filed
recherche médicale – INSERM) is ranked second, with the European Patent Office,
while Assistance Publique – Hôpitaux de Paris (AP- it was ranked
HP) is in 11th place. INSERM is also the leading
5th for biotechnologies
patent applicant with the European Patent
Office (EPO) in the pharmaceutical sector, 6th for medical technologies
and the fourth leading patent applicant (but the
10th for pharmaceuticals
Whether it is through the discovery of the first rabies vaccine by Louis leading academic institution) for biotechnologies.
Pasteur in 1885, or the development of the robotic surgeon Rosa by The French National Center for Scientific Research
the company Medtech, France has always been at the cutting edge of (Centre national de recherche scientifique –
innovation in the healthcare sectors. CNRS) is ranked second among world research
organizations by the Nature Index 2018 due to
the large amount of work published by CNRS
RENOWNED MEDICAL
patient using virtual reality glasses. researchers in acclaimed journals. A researcher from
EXCELLENCE France is the fourth largest holder of patents The French Atomic Energy and Alternative Energy
Commission (Commissariat à l’énergie atomique
INSERM is finalist
in the EPO European
for all sectors combined with the European
et aux energies alternatives – CEA) meanwhile is
France’s medical research stands out for its Patent Office, after the United States, Japan
Inventor Award 2019
part of the 100 top organizations for innovation,
excellence. No fewer than 13 recipients of the and Germany, and was responsible for 6% of all as ranked by Clarivate Analytics in its Derwent Top
Nobel Prize for medicine are French, while patents filed in 2018. In the pharmaceuticals 100 Global Innovators 2018-19.
numerous medical world firsts have taken place sector, France is ranked third after the United
in France, such as: the first carotid stent implant
States and Germany, but ahead of Switzerland. Jérôme Galon, a researcher at
in 1990; the first partial face transplant in 2005;
These figures confirm that France is a leading INSERM, has developed Immunoscore®,
the first Carmat artificial heart implant in 2013; or
a diagnostic tool which can help
the removal of a cerebral tumor from an awake innovative nation.
medical staff to predict the chances of
recovery and risks of relapse in cancer
INSERM : patients based upon the strength of
% share of patent applications to the European Patent Office (EPO) by source country (2018) their immune response. Immunoscore®
uses digital images of tumor samples
• 2nd leading
25 United States and advanced software to measure
healthcare institute
15 Germany the number of positive immune cells
in the world
13 Japan found at tumor sites. Its results have
•#1 academic
Source: European Patent Office
6 France improved the accuracy of cancer
depositor of patents
5 China in pharmaceuticals prognosis and helped tailor therapies
5 Switzerland and biotechnologies to individual patients.
4 South Korea in Europe
4 Netherlands
3 United Kingdom
*Source: Scimago, EPO
3 Italy
2 Sweden
0 5 10 15 20 25 30
811
BUSINESS FRANCE FRENCH HEALTHCARE 2019
member states) in the pharmaceutical sector in
SUBSTANTIAL R&D 2016, after Switzerland, the United Kingdom and
INVESTMENTS
Numerous medical world firsts carried out in France Germany.4
Pharmaceutical businesses employ nearly
1st insulin pump transplant (1981) 18,000 people in R&D activities, including 10,000
With gross domestic expenditure on R&D (GERD)
researchers.5 R&D personnel account for 18% of all
1st carotid stent implant (1990) of €50 billion in 2017, France was the second the workforce in this sector.
1st computer-assisted open heart operation (1998) leading country in Europe after Germany for the
amount it spent on R&D, and was ranked sixth in Sanofi is the French business that invested the most
1st face transplant (2005) the world.1 in R&D in 2017 and 2018 in all sectors. As such, it
is part of the 25 businesses that spent the most
1st use of an autonomous artificial pancreas in everyday life (2011) Healthcare industry businesses invest strongly on R&D worldwide in 2017/2018,6 with €6.6 billion
in R&D. The pharmaceutical industry is the third invested in 2018, or 15% of revenues. In 2018, three
1st Carmat artificial heart implant (2013)
leading sector for business enterprise R&D other businesses from the healthcare industries was
1st implant of a ceramic sternum (2015) expenditure (BERD) in France, after the automotive part of the 25 largest investors in R&D in France:
and aerospace industries. Pharmaceutical Biomérieux (€370 million), Ipsen (€320 million) and
1st removal of a cerebral tumor from an awake patient using virtual reality glasses
businesses committed €3 billion to gross domestic Essilor (€260 million).7
(2016
expenditure on R&D in 2017, or nearly 13% of all
In the medical devices sector, more than half of
etc. business enterprise R&D expenditure by all
all businesses had R&D operations and nearly 13%
manufacturing industries.2
of all businesses were exclusively active in R&D.8
By integrating their external spending, the R&D Moreover, at a European level the field of medical
effort by these businesses was €4.5 billion in technologies was the leading field for filing patents
2015, or nearly 10% of their revenues, which is with the European Patent Office. Essilor, a world
a similar proportion to the automotive industry.3 leader in the corrective lens field, was cited as one
France was the fourth largest R&D spender among of the 100 most innovative businesses in the world
European countries (third among European Union in 2018 by Forbes.
Gross domestic expenditure on R&D (2017) (€ million)
Change in BERD and GERD in France
500,000
Index (base 100 = 2000)
400,000
200
300,000
150
200,000
100,000 100
Source: Eurostat
0 50
s
m
nd
Source: OECD, MSTI
ia
ly
ia
m
nd
en
ce
g)
a
n
n
y
es
re
ai
iu
pa
tr
Ita
ss
an
do
rla
n
an
ed
la
at
Sp
us
lg
Ko
Ru
Ko
Ja
m
er
ng
he
Fr
St
Sw
Be
A
0
er
itz
h
g
Ki
et
d
ut
on
G
Sw
ite
N
d
So
.H
ite
Un
7
97
87
93
3
89
95
1
13
15
17
81
83
85
9
11
91
99
5
0
l
Un
0
0
0
xc
0
20
20
20
20
19
19
20
19
19
19
19
19
19
19
20
19
20
20
20
(e
a
in
BERD GERD
Ch
European Patent Office (EPO)1 - Ministry for Higher Education, Research and Innovation (MESRI), 20192 - Trade Organization of Medical Devices Businesses – LEEM3
- European Federation of Pharmaceutical Industries and Associations – EFPIA4 - French National Institute for Statistics and Economic Studies – INSEE5 - The 2018
EU industrial R&D investment scoreboard6 - PricewaterhouseCoopers (PwC)7 - National Association of the Medical Technologies Industry – SNITEM8
1013
BUSINESS FRANCE FRENCH HEALTHCARE 2019
R&D spending in the pharmaceutical industry (2016) (€ billion) Leading sectors of patent filings with the European Patent Office (2018)
6.4 Switzerland
7.9 Medical technology
6.2 Germany
6.8 Digital communication
5.7 United Kingdom
6.7 Information technology
4.5 France
6.2 Machines and electrical energy
2.9 Belgium
5.2 Transport
1.5 Italy
5.0 Measuring techniques
1.1 Sweden
Source: EPO
4.3 Pharmaceutical products
1.1 Spain
3.9 Biotechnologies
0.6 Netherlands
3.7 Other specialist machines
0.3 Ireland
Source: EFPIA
3.6 Organic fine chemicals
0.3 Austria
0.3 Poland 0 1% 2% 3% 4% 5% 6% 7% 8%
0.2 Finland
0 1 2 3 4 5 6
The “innovative new company” status (jeune
A COUNTRY WHERE IT’S entreprise innovante – JEI), introduced in 2004,
GOOD TO INNOVATE offers a variety of tax and social security relief
(such as partial exemption from corporate tax
Top 25 French businesses to have invested in R&D (2018) and capital gains, and complete exemption from
France has very generous state funding for certain employer social security contributions)
R&D investment (€ billion) R&D intensity R&D, with tax breaks such as the research tax to SMEs that are less than eight years old and
credit, innovation tax credit and the innovative devote at least 15% of their total spending to R&D.
new companies status, but also innovation The Major Investment Plan (Grand Plan
7 45% funding programs such as the Major Investment d’Investissement – GPI) takes on the work of
Plan. France has the highest R&D spending tax the National Investment Program focusing
6 30 % subsidy rate in OECD countries, thanks to the on innovation, such as the innovation contest,
implementation of the research tax credit.1 support for collaborative research, and several
funds operated by Bpifrance to strengthen
The research tax credit (crédit d’impôt recherche
5 25 % the French venture capital market in certain
– CIR) is a tax-incentive scheme to support segments. It corresponds to a €57 billion
research that is open to companies of any size investment program centered on four priorities,
4 20 % and from any sector. The tax credit amounts to including anchoring competitiveness to
30% of R&D expenses up to €100 million and 5% innovation and building a digital state. This major
of expenditure above this threshold. Eligibility for investment program notably includes a provision
3 15 %
the research tax credit was extended in 2013 to of €5 billion to fast-track the digitization of the
encompass innovation spending by SMEs claimed healthcare and social cohesion system.
2 10 % back through the innovation tax credit (20%
Gross domestic expenditure on R&D in France
rate up to €400,000): the expenses in question
was multiplied twofold between 2000 and 2017,
must go towards the design of prototype or pilot
growing more strongly than business enterprise
Source: PwC
1 5%
versions of new products. France’s research R&D expenditure.
tax credit can be used against eligible R&D
0 0 expenditure up until market approval or CE
marking. More than nine in 10 biotech businesses
ce
s
e
ne
S
en
ia
d
a
t
lin
n
n
Pe ult
de
t
o
r E ran
Th al
es
nm l
r L eux
ric
-G l
a
up na
en
eo
de me
em
ng
ai
oM tio
C
le
an
declared having used the research tax credit in
é
ec
t
al
To
t S che
in ran
no
s
ct
ui
a
r
a
ob
de Saf
ro tio
ug
Ip
i
O
gr
en
ra
a
ur
V
tè
ér
rk
iq
le
a
vi
L’
F
2017.2
G
O
Le
a
i
ys
Fa
D
R
A
ai
M
tA
rn
t-
rt
ai
ni nte
bi
ul
te
L’
ité
Sa
ul
G
sa
ei
En
I
sa
ic
co
hn
In ilor
as
tr
as
ft
Sc
D
ec
so
s
D
ge
Es
El
bi
U
OECD1 - France Biotech2
1215
BUSINESS FRANCE FRENCH HEALTHCARE 2019
Change in public support for R&D in France in % of GDP R&D tax subsidy rate in SME beneficiaries (2018)
50%
0.45
43
0.4 40%
0.35 33
30% 31
29
0.3 27
Reform to the research tax credit 20% 22
0.25
(2008) 20
17 16
0.2
10%
9
0.15
55
0%
0.1
-1
Source: OECD
-2
Source: OECD
0.05 -10%
y
s
n
m
n
m
en
ly
d
es
d
ce
nd
ia
0
nd
an
pa
ai
an
an
Ita
tr
do
iu
at
ed
an
la
Sp
m
us
rla
lg
Ja
l
nl
St
Po
Ire
ng
Fr
Sw
er
Be
Fi
A
he
7
2
3
1
14
12
13
15
10
11
0
4
5
6
8
9
d
Ki
0
G
0
0
0
0
0
0
0
0
ite
20
0
et
20
20
20
20
20
20
d
20
20
20
20
20
20
20
20
20
N
Un
ite
Un
R&D tax subsidy rate in large company beneficiaries (2018)
50%
40% 43
METHODOLOGY
FRANCE:
30% 33 #1 country for R&D
The R&D tax subsidy
29 subsidies within
rate corresponds to the
OECD countries
theoretical level of tax
20% 22 thanks to the
support per additional
research tax
10%
17 17 16
13
monetary unit of R&D
spending for which 1 credit, covering
30% of R&D
11 businesses (SMEs or large
expenses up to
9 companies) are eligible.
€100 million
55
Source: OECD
0% *Source: OECD
-1
-2
-10%
y
d
m
ia
n
m
en
ly
n
es
d
ce
d
s
an
nd
ai
n
pa
an
an
tr
Ita
iu
do
at
ed
an
la
Sp
us
m
lg
rla
Ja
nl
l
St
Ire
Po
ng
Fr
Sw
er
A
Be
Fi
he
d
Ki
G
ite
et
d
Un
N
ite
Un
1417
BUSINESS FRANCE FRENCH HEALTHCARE 2019
Healthcare clusters specializing
in medical biotechnologies
Nutrition Santé Longévité, which bring together
A MARKET AT THE HEART 1,300 members, including 1,000 SMEs.
OF EUROPE
A large number of other innovation clusters are
involved in the medical devices sector, such as
the European Center of Ceramics in Limoges,
Innovation clusters play a key role in attractiveness
Minalogic in Grenoble which specializes in digital
and innovation policies by encouraging
technologies, and Optitec, a cluster focusing on
partnerships between research organizations photonics and imaging, located in Marseille.
and business. In healthcare sectors, there are
Some support structures take the form of
numerous innovation clusters spread throughout
business mini-clusters (such as Pôle des
the country.
technologies médicales and Eurasanté), clusters
France has six innovation clusters specifically (I-Care, Polepharma), technology clusters
dedicated to the healthcare, medical (Pôle technologique de Haute-Champagne) or
biotechnology and medical devices sectors: Lyon associations (National Association of the Medical
Technologies Industry – SNITEM).
Biopôle, Medicen, Biovalley France, Atlanpole
Biothérapies, Eurobiomed and
Funds financing innovation healthcare
authorization procedures for clinical trials to
Announced at the 8th Strategic Council of the government’s National Investment EARLY ACCESS reduce the response times for these authorizations
for Healthcare, the venture capital Program, has a budget of €250 million, TO INNOVATIONS and to make France a more attractive country for
fund InnoBio II is designed to invest of which €170 million will be redeployed
clinical trials.
in businesses proposing innovative to cover all medical technologies. This
services close to or at the start of their investment fund is dedicated to developing France is one of the world’s leading players in Temporary use authorizations (autorisations
development in all healthcare fields innovative businesses or for research clinical research. Between 2015 and 2017, it took temporaires d’utilisation – ATUs) is a French
(biopharmaceuticals, medical devices, projects developed by the National part in 12% of industrial trials initiated in the world, scheme allowing early access to new, innovative
e-healthcare, etc.) This fund initiated by Investment Program. It intervenes in seed the fourth highest participation rate in Europe. medicinal products before their marketing
Bpifrance and Sanofi, along with other capital, venture capital and as a hedge France stands out particularly in oncology, as it authorization (autorisation de mise sur le marché –
healthcare players such as Boehringer, fund. hosted nearly one in five clinical trials worldwide AMM) is granted to patients suffering from serious
Ingelheim, Ipsen, Takeda and Servier, aims over this period and took part in nearly one in two or rare illnesses for which no alternative therapy
The innovative biotherapy and rare
to grow to between €150 and €200 million. clinical trials in phase three in this field.1 Clinical exists. This virtually unique scheme in Europe
diseases fund is a seed fund focusing on
trials are a way of early access to innovations for enables rapid access to the most promising
The FABS biotechnology healthcare businesses in the innovative therapies field
French patients. medicinal innovations several months or even
accelerator fund, implemented as part targeting rare diseases.
In 2018, the French Agency for Medicinal and several years before marketing authorization is
Healthcare Products (Agence nationale de granted. Medicinal products which are granted
sécurité du médicament et des produits de for temporary use are reimbursed by the statutory
santé – ANSM) implemented a revision plan of health insurance system.
Source: LEEM, France’s attractiveness for clinical research1
1619
BUSINESS FRANCE FRENCH HEALTHCARE 2019
Participation in oncology clinical trials initiated worldwide (2015-2017)
Founded in 2015, Diabeloop has developed an now underway to expand this solution to the
60% “artificial pancreas”, a system for automatically treatment of other types of cancer.
59.2 managing diabetes type 1, comprising a glucose
measuring cell and an insulin pump that are Specializing in the medical imaging by
50% controlled by artificial intelligence. Diabeloop ultrasounds sector, SuperSonic Imagine has
belongs to two innovation clusters, Medicen developed a technology allowing doctors to
Source: LEEM, France's attractiveness for clinical research
Paris Region and Minalogic in Grenoble visualize and analyze tissue hardness in real
40% (Auvergne-Rhône-Alpes), and has developed a time using a non-invasive procedure, which
technology partnership with the French Atomic remains a key advantage for diagnosing
Energy and Alternative Energy Commission potentially malign lesions or other ill tissue.
30% (CEA). The innovative new company, based in SuperSonic Imagine, which has been listed on
Grenoble, obtained CE marking in November Euronext since April 2014, is based in Aix-en-
2018, enabling its device to be marketed across
22.4 Provence (Provence-Alpes-Côte d’Azur) and has
20% Europe.
19.4 operations in more than 30 countries.
17.6
16.8 16.7 Nanobiotix proposes new therapeutic
15.4 Orange Healthcare launched an e-health
10% 12.6 12.6 approaches to cancer treatment, and has
11.9 11 startup support program in 2019. Prize-winning
developed a solution by which nanoparticles
of cancerous cells can be injected prior to the businesses enjoy access to cut-price healthcare
first radiotherapy session to extend the action. data hosting, as well as software solutions from
0%
Nanobiotix obtained CE marking in 2019 for its its subsidiary Enovacom, and support in the
d
soft-tissue sarcoma treatment, and studies are field of communication.
m
n
da
m
y
n
a
es
ce
ly
an
an
in
ai
pa
Ita
do
iu
at
an
na
Sp
Ch
l
m
lg
Ja
Po
St
ng
Fr
Ca
er
Be
d
Ki
G
ite
d
Un
ite
Un
FRANCE, A HEALTHTECH The Parisian startup Wandercraft has developed Pixium Vision develops innovative methods
COUNTRY AT THE to restore vision, using implantable medical
Atalante, an exoskeleton that can give back
FOREFRONT OF INNOVATION
autonomy and mobility to people in wheelchairs. devices designed to cure blindness caused
It works in conjunction with several academic by the degeneration of photoreceptor cells
France has 18 biotech/medtech startups per million
institutions such as the University of Michigan in the retina. These devices are designed for
inhabitants, more than the United States (10) and the
and the California Institute of Technology in the blind patients whose optical nerve remains
United Kingdom (13).1 Young French entrepreneurs in
the healthcare sector have often received awards. United States, MinesParisTech and the French functional. The business won the Prix Galien
2018 in the category “Research Work”.
National Center for Scientific Research (CNRS)
Yann Fleureau, the co-founder and CEO of Cardiologs,
an artificial intelligence startup which analyzes in France. Its first version has been designed H4D is a French company specializing in
electrocardiograms, has been named among the to be used in reeducation centers. In May 2019, designing telemedicine solutions. It has
Innovators Under 35 list by MIT Technology Review the company obtained CE marking enabling developed the Consult-station, a telemedicine
and European Innovator of the Year 2018. In 2019, 10 it to market across the European Union, and cabin equipped with around thirty medical
French healthcare startups received an innovation received the Robot of the Year in 2018. measuring instruments through which video-
award at the Consumer Electronics Show (CES), conference consultations can be held with
including the brain training solution for better sleep The online healthcare insurance startup Alan, general practitioners and health check-
Urgotech. created in 2016, raised €40 million in February ups can be carried out. The organizations
2019. Alan insures nearly 30,000 people in using this solution include accommodation
Among the 10 SMEs that have filed the most patents
France, mainly independent workers and establishments for elderly people requiring
in France with INPI in 2018, there are two healthtech
employees of micro-businesses and SMEs. By full-time care, hospitals and other businesses.
businesses. Distraimed, which proposes a secure pill
organizer enabling better observance of patients 2020, the business aims to insure 100,000 people H4D is present in seven countries, including the
during treatment; and BioSerenity, which has designed and to multiply its revenues by five. United States.
a piece of smart clothing aiming to more closely follow
and diagnose epilepsy.
France Biotech1
1821
BUSINESS FRANCE FRENCH HEALTHCARE 2019
_2_
FRANCE IS AN OPEN COUNTRY
FRANCE, AN 22
ATTRACTIVE FRENCH HEALTHTECHS RAISE FUNDS
25
COUNTRY FRANCE STANDS OUT IN INTERNATIONAL
RANKINGS FOR THE QUALITY OF ITS
RESEARCH AND ITS INNOVATION CAPACITY
25
THEY CHOSE FRANCE
26
2023
BUSINESS FRANCE FRENCH HEALTHCARE 2019
FRANCE’S
ATTRACTIVENESS
AT A RECORD 320
€
job-creating
HIGH
FRANCE, AN
foreign
1,323 job-creating investment
foreign investment projects between
projects received 2014 and 2018
ATTRACTIVE
in 2018 One project out
28,600 foreign businesses of four
Leading host country of foreign in R&D
industrial investment in Europe
COUNTRY *Source: Business France *Source: Business France
Foreign investment projects in France in
the healthcare sector (2014-2018)
In 2018, France welcomed a record number of investments, with 1,323 job-
creating foreign investment projects being recorded by Business France. 589
340
1,277 1,335
pharmaceuticals and biotechnologies sector 138
FRANCE IS AN OPEN and the medical devices sector. More than half
COUNTRY of these projects came from four countries: the
United States (29% of projects), Germany (12%), 129
855
Italy (9%) and Switzerland (8%). 238
With 28,600 foreign businesses set up, employing
Number of projects
more than two million people and carrying out The high proportion of R&D projects (24%)
21% of R&D expenses and 31% of exports, France’s confirms the perception of France as a country more than 80
attractiveness is particularly strong in industry, suitable for innovation in the healthcare industries.
where for more than 15 years it has been the 40 to 60
leading recipient of foreign industrial investment Projects were mainly located in Ile de France / Paris
in Europe (EY), and 80% of foreign investors region (26% of projects), Auvergne-Rhône-Alpes 20 to 40 606
believe that French industry is attractive (Kantar (14%) and the Grand Est region (12%). In some 1,151
Public – Business France survey). of these regions, investments in these sectors less than 20
represented a significant share of all investment
Between 2014 and 2018, some 320 job-creating projects, for example in the Centre-Val de Loire
foreign investment projects were recorded region, projects in healthcare sectors represented
in the healthcare industry in France. These more than 14% of all projects recorded in the last
projects were evenly distributed between the five years. Number of jobs created 624
694
Source: Business France
2225
BUSINESS FRANCE FRENCH HEALTHCARE 2019
FRENCH HEALTHTECHS FRANCE STANDS OUT IN
INTERNATIONAL RANKINGS
RAISE FUNDS
FOR THE QUALITY OF
ITS RESEARCH AND ITS
French businesses raised €3.525 billion INNOVATION CAPACITY
between 2016 and 2018, making France the
second leading country in Europe, after the
United Kingdom and ahead of Switzerland. In the IMD World Competitiveness Yearbook
Moreover, France is the leading European 2018, France is ranked among the 10 leading
country for companies financed by venture countries in the world for numerous indicators
capital in 2017.1 relating to the quality of its research. France
stands out in terms of the number of Nobel
With more than 90 quoted healthtech businesses Prizes won since 1950 (4th), qualified engineers
(66 of whom are French), with a market available in the labor market (3rd), the total
capitalization of around €23 billion, Euronext number of R&D personnel (7th), private R&D
is the leading European market for businesses
Leading countries for investing in France in the healthcare sectors (2014-2018), % in the sector. In 2018, two French healthtech
spending (6th), the number of patents filed
(6th), and the respect and implementation of
businesses were listed in Paris: Voluntis, founded intellectual property rights (10th).
29.1 United States
in 2001, which designs digital therapy software
12.1 Germany aiming to support patients during treatment, In the WEF Global Competitiveness Report 2018,
8.7 Italy raised €30 million; while Montpellier-based innovation also holds a special place in France,
7.6 Switzerland business MedinCell, specializing in developing which is ranked fourth in the world for R&D, with
long-lasting therapeutic injectable products, renowned scientific institutions (3rd), a large
Source: Annual Report 2014–2018; Business France
6.6 Japan
also raised €30 million on the Euronext market number of quality scientific publications (5th),
5.2 United Kingdom businesses that invest strongly in R&D (13th) and
in Paris.
5.2 Canada file patents (12th).
4.2 Denmark Numerous healthtech startups are among the
largest French fundraisers in 2018. Furthermore, the AmCham Bain survey in 2019
3.8 Sweden shows that 65% of American investors in France
1.7 China Dynacure, which develops treatments for consider that the priority given to R&D is a strong
1.4 Spain patients with rare diseases, raised €47 million, point compared with other European countries,
while Quantum Surgical collected nearly €43 with this value rising to 67% for qualification
1.4 South Korea
million to democratize mini-invasive treatment levels of the workforce.
1.4 South Africa
of liver cancer and Enyo Pharma, which develops
1.4 Netherlands The quality of healthcare infrastructures in
therapeutic molecules to fight acute and chronic
France is acclaimed, with the country ranked
1.4 Brazil viral illnesses, raised €40 million.
10th under this indicator in the IMD World Talent
Founded in 2015, Dental Monitoring, which Report.
0 5% 10% 15% 20% 25% 30% proposes artificial intelligence tools for dentistry
and orthodontics, raised €45 million through
European fund Vitruvian Partners in the first
quarter of 2019.
Finally, Doctolib, an online medical appointment
management service linking patients and
healthcare professionals, raised €150 million in France is among the main drivers of
March 2019 with French and foreign investors in
global innovation. After having seduced
a funding round led by the American firm General
Facebook, which opened its first research
Atlantic. Doctolib has thereby entered into a
center of artificial intelligence outside
very selected circle of ‘unicorns’, or startups
the United States in Paris in 2015, Google
valued at more than €1 billion.
and Microsoft both announced their
intention to create dedicated artificial
intelligence centers in Paris which will
work with others in the healthcare
industry.
France Biotech.1
2427
BUSINESS FRANCE FRENCH HEALTHCARE 2019
PANAXIUM CURA GLOBAL HEALTH
The French subsidiary of Panaxium opened Cura Global Health is an American biotech
its first R&D center in Europe in August 2016 startup that has developed a fermentation
THEY CHOSE near Aix-en-Provence (Provence-Alpes-
Côte d’Azur region), where it develops
process that allows for the high incorporation
of essential nutrients into dietary supplements.
FRANCE bioelectronic devices capable of following
The company relocated its headquarters,
and even acting on the nerve and electrical
currently in Iowa, USA, to Avignon, Provence-
impulses of the human body. Miniaturized cell-
Alpes-Côte d’Azur region, France to strengthen
scale implants aim to deliver nerve electrical
its partnership with Naturex, the Provence-
signals to treat a number of diseases or
Alpes-Côte d’Azur-based global leader in
conditions, such as Parkinson’s, Alzheimer’s,
natural ingredients. This is the company’s first
brain injuries and peripheral nerve damage.
European base, which will serve as a global
decision and R&D center, with the investment
The R&D center currently has 21 employees
NOVARTIS ASTRAZENECA leading to 12 new jobs.
and is made up of a multidisciplinary team
of scientists, including world-class experts
in organic bioelectronics and leaders in the
In the last five years, Swiss business Novartis Anglo-Swedish business AstraZeneca has fields of chemistry, materials science, electrical
has carried out and announced very important invested on a number of occasions at its engineering, systems design, electronic
investment projects in its French industrial regional site in Dunkirk (Hauts de France) over engineering, data science, biochemistry and
plants, consolidating its presence in France. In the last five years, which was founded in 1991 nanotechnology.
2016, it carried out an expansion of its site in to produce inhalers to treat asthma as well as
Huningue (Grand Est region), building a state chronic obstructive pulmonary disease, and
of the art biosimilar production facility after a employs more than 450 people.
financial investment of more than €100 million
A major reinvestment of €135 million was
and the creation of around a hundred jobs over
announced in 2017, expanding production
three years.
activity of medicinal products at the site.
In 2018, Novartis decided to concentrate its The aim is to produce a very high value-
activities producing innovative medicinal added production process concentrating on
products and followed up these investments. inhalation technology. The Dunkirk-based
It acquired the French Advanced Accelerator plant will therefore become a worldwide
Applications (AAA) laboratory, which produces benchmark for the production of inhaled
a new “Lutathera” treatment, a flagship drug, at medicinal products, 90% of whose products
ASPEN HOLDINGS
the beginning of 2018 for nearly US$4 billion. will be exported to the United States.
The five production sites in France will benefit After having invested in R&D at its site in
from this new investment and will see their Notre Dame de Bondeville (Normandie
production activities grow. region), with the creation of a center of
Novartis announced investment projects excellence in thrombosis in 2016, South African
totaling €800 million at the first Choose France pharmaceutical company Aspen has invested
summit. €100 million in its facility producing sterile
injectable drugs.
The site now has a new line of injectable
products, as well as new buildings and a third
filling line for antithrombotic drugs. These
investments will lead to around a hundred new
jobs.
2629
BUSINESS FRANCE FRENCH HEALTHCARE 2019
NOVO NORDISK A/S MERCK KGAA
Danish pharmaceutical company Novo Nordisk, Millipore, specializing in filtration, purification
specializing in the treatment of diabetes, and microbiological control for the
announced a new investment worth €100 pharmaceutical industry and created in 1954
million in 2016 at its site in Chartres (Centre- in the US city of Boston, opened a site near
Val de Loire region). This new investment will Strasbourg (Grand Est region) in 1972, attracted
enable a new generation of insulin pens to be by the Alsatian life sciences ecosystem.
produced, creating 250 jobs.
In 2010, Millipore was acquired by German
company Merck. Driven by a regular investment
policy, the small French site has more than
1,000 employees and has become as a key
player in the sector. Moreover, Merck has
also invested at its site in Martillac (Nouvelle
Aquitaine), leading to the creation of 100 jobs
in R&D and 56 in logistics.
2831
BUSINESS FRANCE FRENCH HEALTHCARE 2019
FRENCH EXPORTS OF
MEDICINAL PRODUCTS
32
EXPERTISE FRENCH EXPORTS OF
MEDICAL DEVICES
GOING GLOBAL 34
REGIONAL BREAKDOWN
OF FRENCH EXPORTS
35
3033
France’s market share in global medicinal product exports (2018)
BUSINESS FRANCE FRENCH HEALTHCARE 2019
16%
16.1
14%
13.1
12%
EXPERTISE
10%
9.2
8%
GOING GLOBAL
8 8
7
6%
5.7
Source: IHS Markit
4% 5.1
4.8
2.5 2.5
2%
2 1.7
1.5 1.3
0%
m
en
da
nd
ce
es
nd
ly
a
k
s
y
n
ia
m
nd
ar
di
an
ai
do
Ita
tr
iu
at
ed
an
na
la
la
Sp
In
In 2018, healthcare industries in France were responsible for more than
m
us
rla
m
lg
St
ng
Ire
er
Fr
Sw
Ca
en
er
A
Be
he
itz
d
Ki
D
G
€35 billion of exports, or 7.4% of all French goods exported, with medicinal
ite
et
Sw
d
Un
N
ite
products accounting for three-quarters of all French exports.
Un
France’s main clients for Change in French exports of healthcare products (base 100 = 2000)
medicinal products (2018)
es
450
at
St
d
ite
FRENCH EXPORTS OF 400
Un
MEDICINAL PRODUCTS
.3
Source: French Customs Authorities
14
14%
350
French exports of medicinal products
12%
300
amounted to €27 billion in 2018, up more
than 2% from 2017. Half of these exports
ly ny
8. Ge ium
250
Ita a
were destined for the European Union. The
6 rm
lg
8. Be
10%
leading destination for French exports was
8
7
8.
the United States, accounting for 14% of 200
m
nd do
value exported, followed by Belgium and
er ing
8%
Germany (9% each). France was the world’s 150
itz d K
la
Sw ite
seventh exporter of medicinal products in
Un
2018, accounting for 5.7% of global exports 100
4
6%
5.
3
5.
Source: IHS Markit
in this sector. France stands out particularly
Sp Jap a
an
in
3. Ch
in the field of vaccines, where it was the 50
C s a ds
lic
n
ng d ub
6
1.6 Ru eri lan
4
ai
world’s fourth leading supplier of vaccines
3.
4%
Hu lan Rep
1.7 Alg her
1.6 ze sia
for human medicine in 2018, and was
3
t
y
0
1.4 Po ch
1.9 Ne
ar
responsible for 13% of global exports worth
2
2.
7
2
3
20 1
14
13
15
16
17
18
0
4
5
10
11
12
6
8
9
2%
0
€3.2 billion. The medicinal products sector
0
0
0
0
0
0
0
0
20
0
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
has a balance of trade well in excess of €7.7
billion, including €2.3 billion from the sale Medicinal products Medical devices
0%
of vaccines.
3235
BUSINESS FRANCE FRENCH HEALTHCARE 2019
France’s market share in global medical devices exports (2018)
20%
19.4
FRANCE, A LEADER IN FRENCH EXPORTS OF
THE FIELD OF VACCINES MEDICAL DEVICES 15%
12.5
France is the world’s fourth largest exporter Exports of medical devices from France
10%
of vaccines destined for human medicine, 10.6
approached €7.5 billion in 2018, up 2.2%. As for
and the third leading exporter of veterinary
medicinal products, Europe is the destination
vaccines.
for the majority of these sales. France’s leading 6.4
5% 5.3
France has world-renowned institutions, such customers include the United States (12% of 4.9
4.7 4.2
as the Institut Pasteur International Network. exports), Germany (12%) and the Netherlands 3.4 3.2
3 3 1.7
Present in 26 countries across all continents, 1.3 1.3
(11%). France carried out 3.4% of global exports
Source: IHS Markit
it brings together 23,000 people within 33 0%
of medical devices, and was ranked as the ninth
establishments conducting 768 projects and
a
ca
s
nd
nd
y
ce
m
an
m
e
ly
es
a
o
nd
re
an
or
in
ic
supplier country.
Ita
do
iu
Ri
at
an
ap
la
la
Ko
Ch
ex
ap
rla
m
lg
plays a major role in the fight against emerging
St
er
Ire
ng
a
Fr
J
M
er
Be
st
ng
he
h
itz
d
Ki
ut
G
Co
ite
Si
et
Sw
infectious diseases worldwide.
So
d
N
Un
ite
Un
France’s main clients for medical devices
(2018)
France’s market share in global vaccine exports (2018)
s
an te
m Sta
y
d
ite
25% 14%
Un
er
s
G
nd
.4
.3
21.8
rla
12
12
he
REGIONAL BREAKDOWN
et
20.1 12%
N
20% OF FRENCH EXPORTS
2
11.
10%
14.9
15% French exports of healthcare products are
13.1
concentrated in a limited number of regions. Four
n
ai
regions – Ile de France (Paris region), Normandie,
6. aly
Sp
8%
m
It
do
8
Grand Est and Auvergne-Rhône-Alpes – account
7
10%
ng
ite m
8.3
for more than two-thirds of French exports from
Ki
u
gi
d
el
d
this sector.
1B
6%
n
Un
rla
5.
Source: IHS Markit
Ch tze
8
4.9
4.
5% Some French regions have a very important
i
a
w
in
3.2
S
specialization in their exports of healthcare
7
1.7 Jap and
3.
2.3 2.2
4
4%
3.
2 2 industry goods, amounting to 19% of value
ol
1.4 Ire n
1.2 Alg nd
a
P
0.8 0.8
1.1 Au eria
0.6
la
0.3
3
exported in the Centre-Val de Loire region and
2.
di ia
0%
1.9
In str
17% in Normandie, when this proportion amounts
a
2%
a
lia
m
ly
to 7.4% nationwide.
es
nd
y
d
da
s
ia
n
m
ce
a
re
nd
an
di
ai
n
Ita
tr
do
iu
tra
at
an
na
la
la
Ko
Sp
In
us
m
la
lg
St
Ire
Po
ng
us
Fr
Ca
er
er
A
Be
h
d
A
Ki
h
ut
G
ite
et
So
d
Un
N
ite
0%
Un
Source: French Customs Authorities
3437
BUSINESS FRANCE FRENCH HEALTHCARE 2019
Share of region in national healthcare goods exports, % Share of healthcare in regional exports, %
7.2 5.1
16.1 16.6
24.2 17.4 8.9 9.6
1.5 4.7
Source: French Customs Authorities; Business France calculations
Source: French Customs Authorities; Business France calculations
0.9 1.5
10.5 19
1.3 2.1
2.9 13.7 4.5 8.1
4
2.6
1.6 1.1
Key: The Normandie region represents 16.1% of national Key: Healthcare products correspond to 16.6% of total
healthcare exports. exports from the Normandie region.
3639
BUSINESS FRANCE FRENCH HEALTHCARE 2019
Publication Director:
Christophe Lecourtier (CEO)
Chief Editor:
Sylvie Montout (Chief Economist)
Redactor:
Manuel Marcias (Economist)
Contributors
Lorena Cabrera, Christine Bagnaro
Translator:
David Williams
Design and layout:
Publishing Department, Business France – May 2019
38Business France is the national agency supporting the international development of the
French economy, responsible for fostering export growth by French businesses, as well as
promoting and facilitating international investment in France.
It promotes France’s companies, business image and nationwide attractiveness as an
investment location, and also runs the VIE international internship program.
Business France has 1,500 personnel, both in France and in 58 countries throughout the
world, who work with a network of partners.
Since January 2019, as part of the reform of the state support system for exports, Business
France has given private partners responsibility for supporting French SMEs and mid-size
companies in the following markets: Belgium, Hungary, Morocco, Norway, the Philippines
and Singapore.
For further information, please visit: www.businessfrance.fr @businessfrance
Business France
77, boulevard Saint-Jacques
75680 Paris Cedex 14
Tél. : +33 1 40 73 30 00
40You can also read
